Evidence map›Paper›PMID 28325909›Full record

ArticleScientific reports2017

NMR monitoring of the SELEX process to confirm enrichment of structured RNA.

Ryo Amano, Kazuteru Aoki, Shin Miyakawa, Yoshikazu Nakamura, Tomoko Kozu, Gota Kawai, Taiichi Sakamoto

Abstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Inside the Black Box: What Makes SELEX Better?Molecules (Basel, Switzerland) · 2019
    Review
  7. Article
  8. Article
  9. Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes.International journal of molecular sciences · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ryo AmanoDepartment of Life and Environmental Sciences, Faculty of Engineering, Chiba Institute of Technology, 2-17-1 Tsudanuma, Narashino, Chiba, 275-0016, Japan.
Kazuteru AokiRibomic Inc., 3-16-13 Shirokanedai, Minato-ku, Tokyo, 108-0071, Japan.
Shin MiyakawaRibomic Inc., 3-16-13 Shirokanedai, Minato-ku, Tokyo, 108-0071, Japan.
Yoshikazu NakamuraRibomic Inc., 3-16-13 Shirokanedai, Minato-ku, Tokyo, 108-0071, Japan.ORCID 0000-0001-8763-0424
Tomoko KozuResearch Institute for Clinical Oncology, Saitama Cancer Center, 818 Komuro, Ina, Kitaadachi-gun, Saitama, 362-0806, Japan.
Gota KawaiDepartment of Life and Environmental Sciences, Faculty of Engineering, Chiba Institute of Technology, 2-17-1 Tsudanuma, Narashino, Chiba, 275-0016, Japan.
Taiichi SakamotoDepartment of Life and Environmental Sciences, Faculty of Engineering, Chiba Institute of Technology, 2-17-1 Tsudanuma, Narashino, Chiba, 275-0016, Japan. taiichi.sakamoto@p.chibakoudai.jp.ORCID 0000-0002-1450-9372

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA aptamers are RNA molecules that bind to a target molecule with high affinity and specificity using uniquely-folded tertiary structures. RNA aptamers are selected from an RNA pool typically comprising up to 10

Indexed as

Aptamers, NucleotideMagnetic Resonance SpectroscopySELEX Aptamer TechniqueAptamers, Nucleotide

Identifiers

PMID28325909
PMCPMC5428055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.